Biogen Stock Soars On Promising Data From Late-Stage Alzheimer’s Drug Trial

Biogen said the drug, known as lecanemab, improved the slowdown in cognitive function and functional decline of patients with early-stage Alzheimer's disease, when compared to use of a placebo in ... Read More

Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial

"This is the first Phase 3 trial of any investigational ... with Aduhelm -- Biogen's FDA-approved Alzheimer's drug -- if patients are enrolled in a clinical trial as a major factor in lowering ... Read More

Eisai's full lecanemab phase 3 trial results for Alzheimer's presented at CTAD

Both Eisai and Biogen ... phase 3 trial of gantenerumab in early Alzheimer’s disease, in yet another setback for an amyloid-targeting drug. For the last few years, Walmart has been promising ... Read More

Annovis Bio Wraps Up Phase II/III Trial for Alzheimer's Drug Buntanetap

The phase II/III trial involved ... neurodegeneration in Alzheimer’s disease. Annovis Bio is unique in that it is believed to be the only company developing a drug for both Alzheimer’s and ... Read More

Chinese pharma claims first Alzheimer's drug approval since 2003

Green Valley said that it is planning a large phase 3 trial across sites in the ... and failed for years to find new drugs for Alzheimer’s although Biogen last month surprised the medical ... Read More

With FDA Accelerated Approval Of Alzheimer’s Drug Lecanemab Likely January 6th, Discussion Turns To Price And Reimbursement

Specifically, ICER’s calculations suggest that the Alzheimer’s Disease drug’s demonstrated benefits in a Phase 3 trial - a modest ... Eisai and Biogen may draw some lessons from the Aduhelm ... Read More

Alzheimer's drug adoption in U.S. slowed by doctors' skepticism

Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi ... released the promising results of its Leqembi trial, some thought ... Read More

The Marathon Journey to the First Alzheimer’s Drugs

In Lemere’s ... phase 3 trial; Johnson & Johnson and Pfizer decided in 2012 to discontinue this drug. Although the drugs failed to help patients, the two studies did mark the first use in ... Read More

Alzheimer's Risks and Treatment

Testing for Alzheimer’s disease can be a long, costly, and tiresome process for patients, but researchers from Brigham and Women’s Hospital have been working to make the testing process easier ... Read More

Corcept reports promising phase 3 trial results for Cushing's drug

MENLO PARK, Calif. - Corcept Therapeutics (NASDAQ:CORT) Incorporated (NASDAQ: CORT), a company specializing in the development of treatments for severe metabolic, oncologic, and endocrinologic ... Read More

Can-Fite's Namodenoson advances in Phase III liver cancer trial

Dr. Ohad Etzion, a key opinion leader in hepatology and the first author of the study, has expressed optimism about the drug's safety profile and its potential as a treatment for liver diseases. In ... Read More

Corcept reports promising phase 3 trial results for Cushing's drug

MENLO PARK, Calif. - Corcept Therapeutics (NASDAQ:CORT) Incorporated (NASDAQ: CORT), a company specializing in the development of treatments for severe metabolic, oncologic, and endocrinologic ... Read More